Showing results (411-420 of 423) with videos related to

Sort By:
Pageof 43
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2014
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signalingBhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, et al.
Gastroenterology Report|May 14, 2026
Development and validation of a real-time computer-aided measuring system for colorectal polyp size (with video)Cheng-Long Wang, Xiang-Yu Sui, Song Zhang, et al.
JAMA Oncology|August 14, 2020
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical TrialKe-Da Yu, Fu-Gui Ye, Min He, et al.
BMJ (Clinical Research Ed.)|October 23, 2024
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trialMin He, Yi-Zhou Jiang, Yue Gong, et al.
American Journal of Epidemiology|February 14, 2012
Derivation and validation of a prediction rule for estimating advanced colorectal neoplasm risk in average-risk ChineseQuan-Cai Cai, En-Da Yu, Yi Xiao, et al.
Neuron|April 20, 2022
Glutamatergic synapses from the insular cortex to the basolateral amygdala encode observational painMing-Ming Zhang, An-Qi Geng, Kun Chen, et al.
Breast Cancer Research and Treatment|April 25, 2012
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancerKe-Da Yu, Ying Zhou, Guang-Yu Liu, et al.
Nature Communications|November 11, 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencingGuan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, et al.
The Lancet. Oncology|January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trialLei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II TrialLi Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Pageof 43